

2923-122
MC:jdh



#18
8/4/03
C. Style
NE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Olaf WILHELM et al.)
Serial No. 09/743,800) Examiner: Hong Liu
Filed: January 19, 2001) Group Art Unit: 1624
For: NOVEL UROKINASE)
INHIBITORS)

SUBMISSION OF TRANSLATION OF PRIORITY APPLICATION


Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Submitted herewith is a certified copy of the translation for European Patent Application No. 98113519.7, filed July 20, 1998, from which priority has been claimed in the above-referenced patent application.

Respectfully submitted,

By


Martha Cassidy
Attorney for Applicants
Registration No. 44,066
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 783-6040


Enclosure(s):
Translator's Declaration
Translated Copy of Application



UNITED STATES PATENT AND TRADEMARK OFFICE

I, Martin Hermann BRUNE BSc, MSc, PhD,
translator to RWS Group plc, of Europa House, Marsham Way, Gerrards Cross,
Buckinghamshire, England declare;

1. That I am a resident of the United Kingdom of Great Britain and Northern Ireland.
2. That I am well acquainted with the German and English languages.
3. That the attached is, to the best of my knowledge and belief, a true translation into the English language of the accompanying copy of the specification filed with the application at the EPO on 20 July 1998 under the number 98113519.7 and the official certificate attached hereto.
4. That I believe that all statements made herein of my own knowledge are true and that all statements made on information and belief are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent application in the United States of America or any patent issuing thereon.


For and on behalf of RWS Group plc

The 10th day of October 2002



Match and Return

#18
7/26/03
C. S. L. B.
N/E

2923-122
MC:jdh

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Olaf WILHELM et al.)
Serial No.: 09/743,800) Examiner: Hong Liu
Filed: April 3, 2001) Group Art Unit: 1624
For: NOVEL UROKINASE)
INHIBITORS)

REQUEST FOR ACKNOWLEDGMENT
OF CLAIM FOR FOREIGN PRIORITY


Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants request acknowledgment in writing of claim for priority of the European Patent Application No. 98 113 519.7 for the above-referenced patent application. This patent application is a 371 of PCT/EP99/05145 filed July 20, 1999. Enclosed please find copies of the executed declaration from the parent international application, which claims the benefit of that foreign application, and the Submission of Translation of Priority Application filed February 11, 2003.

Respectfully submitted,

By


Martha Cassidy
Attorney for Applicants
Registration No. 44,066
ROTHWELL, FIGG, ERNST & MANBECK, P.C.
Suite 701-E, 555 13th Street, N.W.
Washington, D.C. 20004
Telephone: (202) 783-6040

Enclosures

2923-122.req.priority.wpd

Match and Return



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

98113519.7

Der Präsident des Europäischen Patentamts:
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

(signature)

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE

02/08/99

L. POTT



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.
Application no.
Demande n°: 98113519.7

Anmeldetag
Date of filing
Date de dépôt 20/07/98

Anmelder.
Applicant(s)
Demandeur(s)
Willex Biotechnology GmbH
81675 München
GERMANY

Bezeichnung der Erfindung.
Title of the invention
Titre de l'invention:

Novel urokinase inhibitors

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat
State
Pays

Tag
Date
Date

Aktenzeichen
File no
Numero de dépôt

Internationale Patentklassifikation
International Patent classification
Classification internationale des brevets

A61K31/495, A61K31/445, A61K31/195, C07D295/182

Am Anmeldetag benannte Vertragsstaaten
Contracting states designated at date of filing AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LU/MC/NL/PT/SE
Etats contractants désignés lors du dépôt

Bemerkungen
Remarks
Remarques

[illegible rubber stamp]

Our ref:

18061P EP/WWvo

Applicant:

Wilex Biotechnology GmbH

Grillparzer Straße 10B

81675 Munich

DE

Novel urokinase inhibitors

Novel urokinase inhibitors

Description

- 5 The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors in particular for treating malignant tumors and the formation of metastases.
- 10 The ability of solid tumors to spread and metastasize in surrounding tissue correlates with the degradation or transformation of the extracellular matrix (tumor stroma) in the vicinity of the tumor cell and/or with the ability of said tumors to penetrate the basement
- 15 membrane. Although the (patho)biochemical connections have not been completely elucidated yet, the plasminogen activator urokinase (uPA) and the urokinase receptor (uPAR) play a central role. uPA mediates the proteolytic cleavage of plasminogen to give plasmin.
- 20 Plasmin in turn is a protease which has a wide range of actions and is capable of directly breaking down components of the extracellular matrix such as fibrin, fibronectin, laminin and the protein skeleton of proteoglycans. In addition, plasmin can activate
- 25 "latent" metalloproteases and the inactive proenzyme of uPA, pro-uPA.

Tumor cells and non-malignant cells of the tumor stroma synthesize and secrete the enzymatically inactive proenzyme pro-uPA. Proteases such as, for example,

30 plasmin or the cathepsins B and L cleave pro-uPA by limited proteolysis to give the active serine protease HMW-uPA (HMW = high molecular weight). Pro-uPA and the active protease HMW-uPA bind to the cell surface

35 receptor uPAR (CD87). Plasmin(ogen) likewise binds to specific receptors on the plasma membranes of tumor cells which leads to focused and amplified plasminogen activation in the immediate vicinity of the tumor cells. Invasive cells thus are able to break down the

extracellular matrix without finding themselves deprived of the support necessary for directed movement because of proteolysis.

- 5 Various cytobiological studies have shown that the cell-associated plasminogen activator system is of particular importance within the cascade-like reaction pathways of tumor-associated proteolytic systems (Wilhelm et al. (1994 The Urokinase/Urokinase receptor system: A new target for cancer therapy? In: Schmitt M., Graeff H., Kindermann G. (eds.): Prospects in Diagnosis and Treatment of Cancer. International Congress Series, Excerpta Medica 1050, Amsterdam, Elsevier 1994, pp 145-156). Cultures of human colon carcinoma cells showed that their ability to migrate through an extracellular matrix depended on the degree of uPA receptor saturation with active uPA. (Hollas et al., Cancer Res. 51 (1991), 3690-3695). The cell culture model likewise showed a reduction in the invasive potential of cells when PAI-1 (Cajot et al., Proc. Natl. Acad. Sci. USA 87 (1990), 6939-6943) or PAI-2 (Baker et al., Cancer Res. 50 (1990), 4676-4684) inhibited the proteolytic activity of uPA. A similar effect was achieved on inhibition of uPA binding to the cell surface by blocking the receptor by means of proteolytically inactive uPA variants (Cohen et al., Blood 78 (1991), 479-487; Kobayashi et al., Br. J. Cancer 67 (1993), 537-544). Transfection of epidermoid carcinoma cells using a plasmid expressing an antisense transcript of a part of uPAR also reduced the invasivity of said cells by suppressing uPAR synthesis (Kook, EMBO J. 13 (1994), 3983-3991). Antibodies directed against uPA and PAI-1 reduced the invasive potential of lung cancer cells in vitro (Liu et al., Int. J. Cancer 60 (1995), 501-506).

Animal models of tumors were also able to show the influence of the plasminogen activator system on the metastasizing process. Thus, addition of anti-uPA

antibodies almost completely prevented the formation of lung metastases caused by human carcinoma cells in chicken embryos (Ossowski and Reich, Cell 35 (1983), 611-619). Metastasizing human carcinoma cells were
5 transfected using an expression plasmid which encoded a proteolytically inactive, but uPAR-binding uPA mutant. The mouse model showed that carcinoma cells synthesizing inactive uPA produced a significantly smaller number of metastases after injection than
10 nontransfected cells (Crowley et al., Proc. Natl. Acad. Sci. USA 90 (1993), 5021-5025). Moreover, after administration of uPA antisense oligonucleotides, nude mice showed inhibition of intraperitoneal spreading of human ovarian carcinoma cells (Wilhelm et al., Clin.
15 Exp. Metast. 13 (1995), 296-302).

In recent years, the clinical relevance of factors of the plasminogen activator system (uPA, uPAR, PAI-1 and PAI-2) for the prognosis of patients having solid
20 malignant tumors has been intensively studied. In these studies, the uPA antigen content in various tumors (e.g. breast, ovaries, stomach, lung, kidney) proved to be a strong prognostic factor both for the recurrence-free survival and for the mortality (see for example,
25 Schmitt et al., J. Obstet. Gynaecol. 21 (1995), 151-165; Jaenicke et al., Breast Cancer Res. Treat. 24 (1993), 195-208; Kuhn et al., Gynecol. Oncol. 55 (1994), 401-409; Nekarda et al., Lancet 343 (1994), 117; Pedersen et al., Cancer Res. 54 (1994),
30 4671-4675). Likewise, increased concentrations of uPAR in lung cancer tissue (Pedersen et al., supra) and breast cancer tissue (Duggan et al., Int. J. Cancer 61 (1995), 597-600; Ronne et al., Breast Cancer Res. Treat. 33 (1995), 199-207) and also in the case of
35 stomach cancer both in the tumor tissue itself (Heiss et al., J. Clin. Oncol. 13 (1995), 2084-2093) and in tumor cells disseminated into bone marrow (Heiss et al., Nature Medicine 1 (1995), 1035-1039) correlate with a poor prognosis.

The use of synthetic uPA inhibitors makes it possible to suppress invasion and spreading of tumor cells. However, developing specific uPA inhibitors is
5 difficult, since tissue plasminogen activator (tPA) has an identical specificity for cleaving the peptide bond Arg560/Val561 of plasminogen. In most cases therefore, low molecular weight uPA inhibitors also inhibit tPA and thus also tPA-mediated fibrinolysis. In addition,
10 it must be guaranteed that synthetic uPA inhibitors show no strong plasmin inhibition.

Despite these restrictions, some inhibitors are known which have a certain specificity for uPA, but a low
15 inhibition capacity, such as benzamidine derivatives and β -naphthamidine derivatives, the most effective compound inhibiting uPA with $K_i = 2.2 \mu\text{mol/l}$ (Stürzebecher and Markwardt, Pharmazie 33 (1978), 599), or amiloride with $K_i = 7 \mu\text{mol/l}$ (Vassalli and Belin,
20 FEBS. Lett. 214 (1987), 187-191).

Another class of known uPA inhibitors is represented by 4-substituted benzothiophene-2-carboxamidines with $K_i = 0.16 \text{ mmol/l}$ in the case of benzothiophene 623 (Towle et
25 al., Cancer Res. 53 (1993), 2553-2559). These inhibitors have a significantly higher affinity for uPA than for tPA and plasmin. uPAR-bound uPA, too, is inhibited very effectively. Disadvantageously however, the chemical synthesis of these substances is
30 complicated and few possibilities for structural modifications are present or have been demonstrated until now.

Therefore, the development of further uPA inhibitors is
35 very beneficial for further elucidating the role of uPA and uPAR in various diseases, especially in tumor spreading and metastasizing.

N α -Arylsulfonyl and N α -arylsulfonylaminoacyl derivatives of 3-amidinophenylalanine are known as selective inhibitors of thrombin (Markwardt et al., Thromb. Res. 17 (1980), 425-431) or of coagulation factor Xa (Stürzebecher et al., Thromb. Res. 54 (1989), 245-252). WO 92/08709 and WO 94/18185 also disclose the use of amidinophenylalanine derivatives as inhibitors of blood clotting, in particular as inhibitors of thrombin.

Piperidides and piperazides of 3-amidinophenylalanine have been intensively studied, among which lead structures for inhibiting fibrinolytic enzymes have been found (Stürzebecher et al., J. Enzyme Inhibition 9, 87-99, 1995; Stürzebecher et al., J. Med. Chem. 40, 3091-3099, 1997). While Stürzebecher et al. (1995) merely describe inhibition of thrombin, factor Xa, plasmin and trypsin, Stürzebecher et al. (1997) also provide information about inhibiting uPA. N α -2-Naphthylsulfonyl-, N α -2-(2,2,5,7,8-pentamethylchroman-6-yl)sulfonyl- and N α -2-camphor-10-yl-sulfonyl-substituted 3-amidinophenylalaninepiperazides have a K_i for uPA of from 28 to 140 μ mol/l, which is about three orders of magnitude higher than the inhibition constant for thrombin. Thus it was impossible to assume that 3-amidinophenylalanine derivatives are suitable as urokinase inhibitors.

Surprisingly we have found, however, that 3-amidinophenylalanine derivatives substituted in the 2 position by a phenyl radical represent selective uPA inhibitors which are active in vivo.

The present invention relates to novel urokinase inhibitors of the general formula I,

$$\begin{array}{c} \text{CH}_2 - \text{CH} - \text{CO} - \text{R}^1 \\ | \\ \text{NH} \\ | \\ (\text{CO} - \text{CH} - \text{NH})_n - \text{SO}_2 - \text{R}^2 \\ | \\ \text{R}^3 \end{array}$$

R¹ (a) is OH or OR⁴, where R⁴ is unsubstituted or substituted, for example by hydroxyl, carboxyl, sulfonyl, nitro, cyano, oxo and/or halogen, branched or unbranched C₁-C₈-alkyl, C₃-C₈-cycloalkyl or aralkyl, e.g. benzyl or phenylethyl,

(b) represents a group of the formula $-N$ in R^6


(i) R^5 and R^6 are H,

(ii) R⁵ is H and R⁶ is unsubstituted or substituted, for example by hydroxyl, carboxyl, sulfonyl, nitro, cyano, oxo and/or halogen, branched or unbranched C₁-C₈-alkyl, aralkyl, e.g. benzyl or phenylethyl, or C₅-C₈-cycloalkyl,

(iii) R⁵ and R⁶ are in each case independently unsubstituted or substituted, for example by hydroxyl or/and halogen, unbranched or branched C₁-C₄-alkyl or

(iv) R^5 is H and R^6 is $-NH_2$ or is, in particular, an aryl-substituted or heteroaryl-substituted amino group,


(c) represents a group of the formula



5 in which m is the number 1 or 2 and in which one or more of the methylene groups are unsubstituted or substituted, for example by hydroxyl, carboxyl, C₁-C₄-alkyl or aralkyl, e.g. benzyl or phenylethyl, with the group
 10 (c) being racemic or in D or L configuration, and R⁷ has the meaning of R¹ in subsections (a), (b) and (f),

(d) represents a group of the formula

15



20 in which p = r = 1, p = 1 and r = 2 or p = 2 and r = 1 and in which one or more of the methylene groups are unsubstituted or substituted, for example by hydroxyl, carboxyl, C₁-C₄-alkyl or aralkyl, e.g. benzyl or phenylethyl, and R⁷ has the meaning of R¹ in subsections (a), (b) and (f),

25

(e) represents a piperidyl group which is unsubstituted or substituted in one of positions 2, 3 or 4, for example by C₁-C₄-alkyl, C₁-C₃-alkoxy or hydroxyl,

30

where a further aromatic or cycloaliphatic ring, preferably phenyl or cyclohexyl, is fused, where appropriate, to the heterocycloaliphatic rings of the formulae

(c), (d) and (e) in the 2,3 position or the 3,4 position relative to the heteroatom,

(f) represents a group of the formula



in which R⁸ is

- (i) unsubstituted or, for example, C₁-C₆-alkyl-, C₁-C₃-alkoxy-, hydroxyl-, carboxyl, sulfonyl-, nitro-, cyano-, oxo- or/and halogen-substituted C₁-C₆-alkyl or aryl, such as, for example, phenyl, p-halophenyl or naphthyl,
- (ii) saturated or unsaturated, branched or unbranched C₁-C₆-alkoxy or
- (iii) unsubstituted or, for example, C₁-C₆-alkyl-, C₁-C₃-alkoxy-, hydroxyl-, carboxyl-, sulfonyl-, nitro-, cyano-, oxo- or/and halogen-substituted phenoxy or benzyloxycarbonyl,

(g) represents an acyl radical of the formula -COX, where X is

- (i) H or unsubstituted, for example hydroxyl-, carboxyl-, sulfonyl-, nitro-, cyano-, oxo- or/and halogen-substituted, unbranched or branched alkyl, preferably C₁-C₆-alkyl, in particular methyl,
- (ii) unsubstituted or, for example, C₁-C₆-alkyl-, C₁-C₃-alkoxy-, hydroxyl-, carboxyl-, sulfonyl-, nitro-, cyano-, oxo- or/and halogen-substituted aryl or heteroaryl, such as, for example, phenyl, p-halophenyl or thienyl, or
- (iii) unsubstituted or, for example, hydroxyl-, carboxyl-, sulfonyl-, nitro-, cyano-, oxo- or/and halogen-substituted cycloalkyl, preferably C₃-C₁₀-cycloalkyl,

(h) represents aralkyl, e.g. benzyl or phenylethyl, in which the aromatic radical is unsubstituted or substituted, for example by halogen, C₁-C₆-alkyl, C₁-C₃-alkoxy, hydroxyl, cyano, carboxyl, sulfonyl or nitro,

(i) represents a carboxamide radical of the formula -CONR'R" a thiocarboxamide radical -CSNR'R", or an acetamide radical -CH₂-CONR'R" where

(i) R' and R" are H,

(ii) R' and R" are in each case independently C₁-C₄-alkyl,

(iii) R' is H and R" is C₁-C₄-alkyl,

(iv) R' is H and R" is aryl, e.g. phenyl, or

(v) R' and R" constitute together with the nitrogen atom a heterocycloaliphatic ring having 5-7 ring members and possibly having a further heteroatom, e.g. N, O or/and S,

(j) represents SO₂-Y where Y is

(i) unsubstituted or, for example, hydroxyl-, carboxyl-, sulfonyl-, nitro-, cyano-, oxo- or/and halogen-substituted C₁-C₈-alkyl, preferably methyl, trifluoromethyl, trichloromethyl,

(ii) unsubstituted or, for example, C₁-C₆-alkyl-, C₁-C₃-alkoxy-, hydroxyl-, carboxyl-, sulfonyl-, nitro-, cyano-, oxo- or/and halogen-substituted aryl or heteroaryl, such as, for example, phenyl, 4-methylphenyl, 2,4,6-trimethylphenyl, 2,4,6-triisopropylphenyl, 4-methoxy-2,3,6-trimethylphenyl, 2,2-dimethyl-6-methoxychromanyl, 2,2,5,7,8-pentamethylchromanyl, anthraquinonyl,

naphthyl or quinolyl, or O-aryl, preferably O-phenyl or O-heteroaryl or (iii)-NR'R", where R' and R" are in each case independently H or C₁-C₃-alkyl,

5

(k) represents a cycloaliphatic ring having from 5 to 8 carbon atoms, which is unsubstituted or substituted, for example by C₁-C₆-alkyl, C₁-C₃-alkoxy, halogen, hydroxyl or/and oxo,

10

(l) represents an unsubstituted or, for example, C₁-C₆-alkyl-, C₁-C₃-alkoxy-, hydroxyl-, carboxyl-, sulfonyl-, nitro-, cyano-, oxo- or/and halogen-substituted heteroaryl radical such as, for example, pyridyl or pyrimidyl, or heterocycloaliphatic radical, for example N-methylpiperidyl,

15

(m) represents a functionalized alkyl radical of the formula -(CH₂)_n-X, where the alkyl chain is unbranched or branched, n = 1 to 8, and the functional radical X

20

(i) represents a hydroxyl group whose hydrogen atom is unsubstituted or substituted by C₁-C₄-alkyl, aralkyl, e.g. benzyl or phenylethyl, aryl, e.g. phenyl, C₁-C₄-hydroxyalkyl or acyl group CO-alkyl, (C₁-C₆),

25

(ii) is a halogen atom,

30

(iii) represents a tertiary amino group of the formula -N(alk)₂, where the alkyl groups have 1 to 3 carbon atoms and are preferably the same, and the nitrogen atom may belong to a heterocycloaliphatic ring having 5-7 ring members and possibly having a further heteroatom, e.g. N, O or/and S,

35

R² represents unsubstituted or, for example, C₁-C₆-alkyl-, C₁-C₃-alkoxy-, hydroxyl-, carboxyl-, sulfonyl-, nitro-, cyano-, oxo- or/and halogen-substituted phenyl, such as, for example, phenyl,
5 4-methylphenyl, 2,4,6-trimethylphenyl, 2,4,6-triisopropylphenyl, 4-methoxy-2,3,6-trimethylphenyl,

R³ is H or branched or unbranched C₁-C₄-alkyl, and n is 0 or 1.

10

The compounds may also be present as salts, preferably as physiologically tolerated acid salts, for example as salts of mineral acids, particularly preferably as hydrochlorides, or as salts of suitable organic acids.

15

Of the compounds defined in the general claims, those are of particular importance in which R¹ corresponds to a group of the formulae (b), (d) and (f), R² represents phenyl mono-, di- or trisubstituted by alkyl, in
20 particular 2,4,6-substituted phenyl, e.g. 2,4,6-triisopropylphenyl, and n = 0.

It is possible to prepare the compounds of the general formula I in a manner known in principle, for example
25 as described in WO 92/08709 and WO 94/18185, and to assay their biological in vitro activity.

(L)-, (D) or (D,L)-3-cyanophenylalanine methyl ester hydrochloride is reacted with an appropriate sulfonyl
30 chloride or a sulfonated amino acid or the halide thereof in the presence of a base to give a compound of the general formula I, which has a cyano function and in which R¹ = OCH₃ and R² and also R³ and n correspond to the meanings defined in the general claims. Mild acidic
35 or alkaline hydrolysis produces therefrom the compounds of the general formula I, which have carboxylic acid structure (R¹ = -OH) and whose acid-catalyzed esterification with an appropriate alcohol leads to compounds of the general formula I, where R¹ = (a).

Applying a method common in peptide chemistry, for example DCC in the presence of HOBT, reacting the carboxylic acids of the general formula I ($R^1 = OH$) with a nucleophile of the structures (b), (e) and (f) may
5 give compounds with the corresponding R^1 of the general formula I. To synthesize compounds with $R^1 = (c)$ and (d), carboxylic acids of the general formula I with $R^1 = OH$ are first reacted with cycloaliphatic amino acid esters of the structures (c) and (d), where R^7 is
10 preferably $-OCH_3$ or OC_2H_5 , the carboxylic esters obtained are hydrolyzed under mild acidic or alkaline conditions to give the corresponding carboxylic acids which may subsequently be esterified in a manner already described or be reacted with nucleophiles of the
15 structures (b), (e) and (f), and compounds of the general formula I with $R^1 = (c)$ and also (d) and with $R^7 = (a)$, (b), (e) and (f) are obtained.

The target compounds of the general formula I, which
20 have amidine structure, are obtainable from the cyano compounds in a known manner; normally, the thioamides are obtained first by addition of H_2S to the cyano group, and are converted by S-methylation with methyl iodide into the thioimido esters and then into the
25 amidino compounds by treatment with ammonium acetate in alcoholic solution. In addition and where appropriate, it is possible, using methanol or ethanol in the presence of HCl gas and, in particular cases, of an inert solvent, to prepare from the cyano compounds the
30 corresponding imido ester hydrochlorides, which are reacted in alcoholic ammonia solution to give the amidino compounds.

The urokinase inhibitors according to the invention may
35 be used, where appropriate, together with at least one suitable pharmaceutical excipient or carrier for producing orally, subcutaneously or intravenously administrable medicaments for controlling tumors or for diagnosis. Likewise possible is administration in

combination with other active substances, for example other urokinase inhibitors such as antibodies or/and peptides.

5 The medicaments for controlling tumors in humans and animals may be administered topically, orally, rectally or parenterally, e.g. subcutaneously or intravenously, in the form of tablets, coated tablets, capsules, pellets, suppositories, solutions or transdermal
10 systems such as plasters.

A particularly preferred compound of the formula (I) is Na-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(D,L)-phenylalanine 4-ethoxycarbonylpiperazide hydrochloride
15 or the L enantiomer thereof or a pharmaceutically suitable salt of these compounds. These substances have good solubility. They are soluble in Tris buffer (pH 7.3) up to a concentration of 5×10^{-5} mol/l. Addition of 5% ethanol increases the solubility to 2×10^{-4} mol/l
20 and addition of 5% DMSO to 10^{-3} mol/l.

The compounds of the invention are capable of very effectively inhibiting the growth or/and spreading of malignant tumors, for example tumor spreading of
25 pancreatic carcinoma, tumor growth of breast carcinoma and also metastasizing of tumors. It is possible to use the uPA inhibitors, where appropriate, together with other anti-tumor agents or with other types of treatment, e.g. radiation or surgery. Furthermore, the
30 inhibitors according to the invention are also effective in other uPA-associated disorders (e.g. in preventing formation of blisters in the case of the skin disorder pemphigus vulgaris).

35 uPA inhibitors according to the invention are preferably characterized in that they have a K_i which is at least twofold, preferably at least 5-fold and particularly preferably at least 10-fold lower for uPA than for tPA. It is furthermore remarkable that the

compounds of the invention only marginally affect blood clotting, since their K_1 is too high for effective inhibition of thrombin and factor Xa.

- 5 The following examples are intended to illustrate the invention in more detail.

Examples

- 10 1. $N\alpha$ -2,4,6-Triisopropylphenylsulfonyl-(L)-3-amidino-phenylalanine 4-ethoxycarbonylpiperazide hydrochloride

- 15 1.1 $N\alpha$ -2,4,6-Triisopropylphenylsulfonyl-(L)-3-cyano-phenylalanine methyl ester

5 g of (L)-3-cyanophenylalanine methyl ester were suspended in 100 ml of dioxane, 4.45 ml of N-methylmorpholine (NMM) were added and the mixture was stirred for 30 min. After adding 5.97 g of 2,4,6-triisopropylbenzenesulfonyl chloride in solid form and subsequent stirring for 3 days, precipitated NMM-HCl was filtered off, the solvent was distilled off and the crude product obtained was purified on silica gel (SG) 60 (chloroform). Yield: 8.34 g of syrup (90%).

- 25 1.2 $N\alpha$ -2,4,6-Triisopropylphenylsulfonyl-(L)-3-cyano-phenylalanine

30 8.34 g of compound 1.1 were heated under reflux in a mixture of 50 ml each of acetic acid and 1 N hydrochloric acid for 8 h and, after cooling, extracted twice with ethyl acetate; the combined ethyl acetate solutions were dried over $MgSO_4$ and the solvent was distilled off. After purification on SG 60 (chloroform), 5.8 g of a solid product were obtained (72%).

1.3 N α -2,4,6-Triisopropylphenylsulfonyl-(L)-3-cyano-phenylalanine 4-ethoxycarbonylpiperazide

5.7 g of compound 1.2 were dissolved in 100 ml of tetrahydrofuran (THF) and cooled to 0°C; 2.22 g of α -hydroxybenzotriazole (HOBt) and 2.82 g of dicyclohexylcarbodiimide (DCC) were added and the mixture was stirred for 30 min. After adding 3.94 g of 1-ethoxycarbonylpiperazine in 30 ml of THF and subsequent stirring overnight, precipitated dicyclohexylurea (DCU) was filtered off, the solvent was distilled off and the crude product obtained was purified on SG 60 (chloroform). Yield: 7.1 g of an amorphous powder (96%).

1.4 N α -2,4,6-Triisopropylphenylsulfonyl-(L)-3-amidino-phenylalanine 4-ethoxycarbonylpiperazide hydrochloride

7.1 g of compound 1.3 were dissolved in 30 ml of pyridine, 30 drops of triethanolamine (TEA) were added, a vigorous stream of hydrogen sulfide was introduced for 10 min, and the mixture was left at room temperature for 2 days. The solvent was then distilled off, the residue was dissolved in ethyl acetate, the organic phase was washed with 1 N hydrochloric acid and saturated sodium chloride solution and dried over MgSO₄, and the solvent was distilled off. 7.2 g of thioamide obtained in this way were dissolved in 250 ml of acetone, 17 g of methyl iodide were added to the solution, and the mixture was left at room temperature under protection from light for 2 days. The solvent was then distilled off, the thioimido ester hydroiodide (8.5 g) was dissolved in 50 ml of methanol, 1.9 g of ammonium acetate were added and the mixture was heated to 60°C for 4 h. After distilling off the solvent, the crude product

obtained was purified on Sephadex LH20 (methanol). The amidine hydroiodide obtained in this way was converted into the hydrochloride via an ion exchange column (Amberlite IRA-420). Yield: 5.3 g of an amorphous powder (69%).

2. Na-2,4,6-Triisopropylphenylsulfonyl-(D,L)-3-amidinophenylalanyl nipecotic acid benzylamide hydrochloride

2.1 Ethyl Na-2,4,6-triisopropylphenylsulfonyl-(D,L)-3-cyanophenylalanyl nipecotate

4.56 g of Na-2,4,6-triisopropylphenylsulfonyl-(D,L)-3-cyanophenylalanine (prepared from (D,L)-3-cyanophenylalanine methyl ester hydrochloride and the appropriate sulfonyl chloride analogously to 1.1 and 1.2), 1.5 g of HOBt and 2.42 g of DCC were dissolved in 50 ml of DMF; the mixture was stirred for 1 h, and then 2.36 g of ethyl nipecotate were added. After stirring overnight, precipitated DCU was filtered off, the solvent was distilled off and the residue was dissolved in a small amount of methanol and left to crystallize. The precipitate formed was filtered off with suction, washed with methanol and dried. Yield: 4.46 g (75%).

2.2 Na-2,4,6-Triisopropylphenylsulfonyl-(D,L)-3-cyanophenylalanyl nipecotic acid

4.4 g of the above-described ethyl ester were heated under reflux in a mixture of 35 ml of acetic acid and 25 ml of 1 N HCl for 2 h. After adding 10 ml of water, the mixture was left to cool, and a wax-like product precipitated. After decanting the solvent, 200 ml of water were added, the mixture was stirred over a relatively long period, and the solid substance obtained was

filtered off with suction, washed with water and dried. Yield: 3.84 g (92%).

2.3 Na-2,4,6-Triisopropylphenylsulfonyl-(D,L)-3-
cyanophenylalanyl nipecotic acid benzylamide

2.28 g of the above-described compound, 0.6 g of HOBt and 0.97 g of DCC were dissolved in 20 ml of DMF and the mixture was stirred for 1 h; 0.6 g of benzylamine was then added, and stirring continued overnight. After filtering off the precipitated DCU, the solvent was distilled off, the residue was dissolved in methanol and the solution was poured into 5% strength sodium hydrogen carbonate solution/ice. After 1 h, the precipitate formed was filtered off with suction, washed with water and dried in vacuo. Yield: 2.48 g (94%).



2.4 Na-2,4,6-Triisopropylphenylsulfonyl-(D,L)-3-
amidinophenylalanyl nipecotic acid benzylamide
hydrochloride

2.4 g of compound 2.3 were dissolved in 30 ml of pyridine, 30 drops of triethanolamine (TEA) were added, a vigorous stream of hydrogen sulfide was introduced for 10 min, and the mixture was left at room temperature for 2 days. The solvent was then distilled off, the residue was dissolved in ethyl acetate, and extracted with 1 N hydrochloric acid. After washing the organic phase with saturated sodium chloride solution and drying over sodium sulfate, the solvent was distilled off. 2.38 g of the thioamide obtained in this way were dissolved in 100 ml of acetone, 6.5 g of methyl iodide were added to the solution, and the mixture was left at room temperature under protection from light for 20 h. The solvent was then distilled off, the thioimido ester hydroiodide was dissolved in 50 ml of methanol, 0.5 g of ammonium acetate was added

and the mixture was heated to 60°C in a water bath for 4 h. After distilling off the solvent, the crude product obtained was purified on SG 60. Elution was carried out first with chloroform, then with chloroform/methanol 9:1. The amidine hydroiodide obtained in this way was converted into the hydrochloride on an ion exchange column (Amberlite IRA-420). Yield: 1.45 g of an amorphous powder (56%).

The compounds were characterized using mass spectrometry, and purity was checked by means of TLC and HPLC.

3. In vitro inhibition of urokinase by selected compounds of the formula I

Configuration	R ¹	R ²	n	K _i , μmol/l
L		TIPP	0	0.41
D,L		TIPP	0	0.61

Abbreviations: TIPP - 2,4,6-triisopropylphenyl

Determination of inhibition activity

To determine the inhibitory activity, 200 μl of Tris buffer (0.05 mol/l, containing the inhibitor, 0.154 mol/l NaCl, 5% ethanol pH 8.0), 25 μl of substrate (Pefachrome UK or Bz-βAla-Gly-Arg-pNA in H₂O; Pentapharm Ltd., Basle, Switzerland) and 50 μl of sc-urokinase (Ribosepharm GmbH, Haan, Germany) were incubated at 25°C. After 3 min the reaction was stopped by adding 25 μl of acetic acid (50%), and the absorption at 405 nm was determined by means of a Microplate Reader (MR 5000, Dynatech, Denkendorf, Germany). K_i values were determined according to Dixon by linear regression using a computer program. The K_i values are the mean values of at least three

determinations with a standard deviation of less than 25%.

4. In vitro inhibition of various serine proteases of the trypsin type by (Na-2,4,6-triisopropylphenyl-sulfonyl-(L)-3-amidinophenylalanine 4-ethoxycarbonylpiperazide (uPA inhibitor) compared with Na-2-naphthylformyl-3-amidinophenylalanine N'-methylpiperazide (naphthyl derivative)

Enzyme	Ki [μ mol/l]	
	uPA-Inh.	Naphthylsulfonyl derivative
Urokinase	0.41	150
Plasmin	0.39	55
Sc-tPA	4.9	430
Thrombin	0.27	0.036
Factor Xa	1.7	30
Factor XIIa	13	1000
Plasma kallikrein	7.2	85
Glandular kallikrein	> 1000	> 1000
Trypsin	0.037	1.3
Tryptase	6.3	33

The inhibition activities of the enzymes used were determined according to the principle described in Example 3.

The values given above indicate that the uPA inhibitor according to the invention has a K_i for urokinase which is more than ten times smaller than the K_i for single chain tPA (Sc-tPA). Thus, the substances of the invention are suitable as selective urokinase inhibitors. For comparison, the inhibitory activity of the naphthyl derivative is given which has a significantly lower in vitro anti-uPA activity.

5. Cytotoxicity determination

To determine cell proliferation/cytotoxicity a commercially available test was used (Promega) which is based on the cellular conversion of a tetrazolium salt. The colored product resulting from this reaction can be quantified by means of an ELISA spectrometer (ICN flow). The synthetic inhibitor (open circles) had no effect on the growth of the human ovarian carcinoma cells OV-MZ-6 (Figure 1) when compared with the solvent alone (closed circles). Thus, the inventive uPA inhibitor is not cytotoxic in pharmacologically effective concentrations up to 40 μ M.

6. Inhibition of the degradation by human breast carcinoma cells of a fibrin matrix

To study the potential of tumor cells for breaking down an extracellular matrix, a fibrin matrix degradation assay was developed and used. A greater proteolytic activity of the tumor cells leads to a higher concentration of fibrin degradation products in the matrix supernatant. The matrix degradation capacity corresponds to the concentration of fibrin degradation products which are determined by means of ELISA (D dimer).

The fibrin gels were prepared in 24-well culture dishes from 200 μ l of fibrinogen (50 mg/ml) in PBS (pH 7.4), by 50 μ l of thrombin (10 U/ml) and 50 μ l of CaCl_2 (150 mM) per well after incubation at 37°C for 30 minutes. 2×10^5 breast carcinoma cells were seeded on said fibrin matrix in 1 ml of DMEM culture medium plus 10% fetal calf serum and 2 μ g of Glu-plasminogen, and incubated for 4 h. The supernatant was then centrifuged, in order to remove the cells, and the fibrin degradation products were quantified by means of ELISA. Adding the inhibitor (A) at different concentrations caused significant inhibition of matrix

degradation by breast carcinoma cells compared with the naphthyl derivative (B) which shows no inhibition of fibrin degradation by breast carcinoma cells (Figure 2).

5

7. In vitro assay of the uPA inhibitor for tumor spreading, tumor growth and metastasizing

A) Breast cancer model

10

10-25 mm³ of breast cancer tumor fragments from rats were transplanted submammary into rats (Day 0). The treatment of the animals was started intraperitoneally 24 hours after tumor inoculation. Each group consisted of eight animals. The control group received only the injection solution (100 µl of a 10% ethanol in saline solution). A dose of 1 mg/kg body weight was intraperitoneally administered on a daily basis to the comparative group of the naphthyl derivative (B) and to the therapy group of the inventive uPA inhibitor (A). The wet weight of the organs was determined directly after the animals had been sacrificed. The treatment was carried out over a period of 4 weeks.

15

20

25

Treatment with uPA inhibitor (A) resulted in a significant reduction in the weight of the primary tumor and also of the axillary lymph nodes ($p = 0.003$ and $p = 0.005$) compared with the naphthyl derivative (B) and control groups without inhibitor (Figs. 3 and 4). The weights of lung, liver, kidney and spleen were unchanged in the animals treated with the uPA inhibitor compared to the control animals.

30

35

B) Pancreatic carcinoma model

Pancreatic tumor fragments from rats were transplanted subcutaneously into rats. The treatment procedure and also the composition of the therapy groups were the same as under A).

Figure 5 shows for the inventive uPA inhibitor (open circles) a significant reduction in tumor weight and a decrease in the growth of developing rat pancreatic carcinomas compared to the naphthyl derivative (closed circles) and the control group (triangles).

C) Treatment of human breast cancer cells in nude mice

In order to test the in vivo efficacy of the inhibitor for inhibiting tumor growth of human breast carcinoma cells (MDA-BA-231), 6×10^6 cells were injected subcutaneously into the right flank of Balb/c nude mice (4-6 weeks old). The tumor cells were preincubated with the synthetic uPA inhibitor prior to inoculation. After 24 h, the mice were treated twice a week intraperitoneally with a dose of 1.2 mg/kg body weight as described under A). The tumor size was determined weekly by measuring the two largest diameters.


Figure 6 shows that the tumor volume increases significantly more slowly on administration of the uPA inhibitor (open circles) than in the control group (closed circles) in which ethanol in saline was administered.

[illegible rubber stamp]

Claims

1. The use of compounds of the formula I

5



which are present as racemates and also as D- or L-configured compounds and in which

10

- R^1 (a) is OH or OR^4 , where R^4 is unsubstituted or substituted, branched or unbranched C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl or aralkyl,

- (b) represents a group of the formula $\begin{array}{c} \text{R}^5 \\ \diagup \\ \text{N} \\ \diagdown \\ \text{R}^6 \end{array}$

15


in which

- (i) R^5 and R^6 are H,
- (ii) R^5 is H and R^6 is unsubstituted or substituted, branched or unbranched C_1 - C_8 -alkyl, aralkyl or C_5 - C_8 -cycloalkyl,
- (iii) R^5 and R^6 are in each case independently unsubstituted or substituted, branched or unbranched C_1 - C_4 -alkyl or
- (iv) R^5 is H and R^6 is $-\text{NH}_2$ or is, in particular, an aryl-substituted or heteroaryl-substituted amino group,

20


- (c) represents a group of the formula

25



in which m is the number 1 or 2 and in which one or more of the methylene groups are unsubstituted or substituted, with the group (c) being racemic or in D or L configuration, and R⁷ has the meaning of R¹ in subsections (a), (b) and (f),

(d) represents a group of the formula




in which p = r = 1, p = 1 and r = 2 or p = 2 and r = 1 and in which one or more of the methylene groups are unsubstituted or substituted and R⁷ has the meaning of R¹ in subsections (a), (b) and (f),

(e) represents a piperidyl group which is unsubstituted or substituted in one of positions 2, 3 or 4,

where a further aromatic or cycloaliphatic ring is fused, where appropriate, to the heterocycloaliphatic rings of the formulae (c), (d) and (e) in the 2,3 position or the 3,4 position relative to the heteroatom,

(f) represents a group of the formula



5 in which R^8 is

- (i) unsubstituted or substituted C_1 - C_6 -alkyl or aryl,
- (ii) saturated or unsaturated, unbranched or branched C_1 - C_6 -alkoxy or
- 10 (iii) unsubstituted or substituted phenoxy or benzyloxycarbonyl,

(g) represents an acyl radical of the
15 formula -COX , where X is

- (i) H, unsubstituted or substituted, unbranched or branched alkyl
- (ii) unsubstituted or substituted aryl or heteroaryl, or
- 20 (iii) unsubstituted or substituted cycloalkyl,

(h) represents aralkyl in which the aromatic
radical is unsubstituted or substituted,

25

(i) represents a carboxamide radical of the formula $\text{-CONR}'\text{R}''$, a thiocarboxamide radical, $\text{-CSNR}'\text{R}''$ or an acetamide radical $\text{-CH}_2\text{-CONR}'\text{R}''$ where

30

- (i) R' and R'' are H,
- (ii) R' and R'' are in each case independently C_1 - C_4 -alkyl,
- (iii) R' is H and R'' is C_1 - C_4 -alkyl,
- (iv) R' is H and R'' is aryl, or
- 35 (v) R' and R'' constitute together with the nitrogen atom a

heterocycloaliphatic ring having 5-7 ring members and possibly having a further heteroatom,

- 5 (j) represents $\text{SO}_2\text{-Y}$ where Y is
- (i) unsubstituted or substituted $\text{C}_1\text{-C}_8\text{-alkyl}$,
 - (ii) unsubstituted or substituted aryl or heteroaryl or O-aryl or O-heteroaryl or
 - 10 (iii) -NR'R'' , where R' and R'' are in each case independently H or $\text{C}_1\text{-C}_3\text{-alkyl}$,
- 15 (k) represents a cycloaliphatic unsubstituted or substituted ring having from 5 to 8 carbon atoms,
- (l) represents an unsubstituted or substituted heteroaryl or heterocycloaliphatic radical,
- 20
- (m) represents a functionalized alkyl radical of the formula $\text{-(CH}_2\text{)}_n\text{-X}$, where the alkyl chain is unbranched or branched, $n = 1$ to 8, and the functional radical X
- 25 (i) represents a hydroxyl group whose hydrogen atom is unsubstituted or substituted by $\text{C}_1\text{-C}_4\text{-alkyl-}$, aralkyl-, e.g. benzyl or phenylethyl, aryl, $\text{C}_1\text{-C}_4\text{-hydroxyalkyl}$ or acyl group $\text{CO-alkyl (C}_1\text{-C}_6\text{)}$,
 - 30 (ii) is a halogen atom
 - (iii) represents a tertiary amino group of the formula -N(alk)_2 , where the alkyl groups have 1 to 3 carbon atoms and the nitrogen atom may belong to a heterocycloaliphatic ring having 5-7 ring members and
 - 35

possibly having a further
heteroatom, S,

5 R^2 represents unsubstituted or substituted
phenyl,

R^3 is H or branched or unbranched C_1 - C_4 -alkyl,
and n is 0 or 1,

10 or of salts of said compounds for preparing an
agent for the diagnosis, therapy and prevention of
urokinase-associated or urokinase receptor-
associated disorders.

15 2. The use as claimed in claim 1,
characterized in that
 R^1 is a group of the formulae (b), (d) and (f), R^2
represents 2,4,6 triisopropylphenyl, and n = 0.

20 3. The use as claimed in claim 1 or 2,
characterized in that
the compound of the formula I is N α -(2,4,6-triiso-
propylphenylsulfonyl)-3-amidino-(D,L)-phenyl-
alanine 4-ethoxycarbonylpiperazide, is the L
25 enantiomer or a pharmaceutically suitable salt of
one of the compounds.

4. The use as claimed in any of claims 1 to 3,
characterized in that
30 the compounds are present in the form of
physiologically tolerated acid salts, in
particular as hydrochlorides.

5. The use as claimed in any of claims 1 to 4 for
35 controlling tumors.

6. The use as claimed in claim 5 for controlling
breast carcinomas, pancreatic carcinomas and the
formation of metastases.

7. The use as claimed in any of claims 1 to 4 for controlling pemphigus vulgaris.
- 5 8. The use as claimed in any of claims 1 to 7 for preparing medicaments which are administrable orally, topically, rectally or parenterally.
- 10 9. The use as claimed in any of claims 1 to 8 in the form of tablets, coated tablets, capsules, pellets, suppositories, solutions or transdermal systems such as plasters.
- 15 10. A method for inhibiting urokinase in living creatures, in particular in humans, by administering an effective quantity of at least one urokinase inhibitor as claimed in any of claims 1 to 4.
- 20 11. $\text{Na}(2,4,6\text{-Triisopropylphenylsulfonyl})\text{-3-amidino-}$
(D,L)-phenylalanine 4-ethoxycarbonylpiperazide, the L enantiomer thereof or a pharmaceutically suitable salt of one of the compounds.

[illegible rubber stamp]

Abstract

The invention relates to the use of derivatives of 3-
5 amidinophenylalanine as urokinase inhibitors for
treating malignant tumors and the formation of
metastases.

10 VO July 20, 1998